PhRMA’s 2018 Special 301 Submission targets Australia, Canada, S. Korea, Japan & others over pricing, reimbursement policies
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading